FLT3 Pre-design Chimera RNAi
產品名稱： FLT3 Pre-design Chimera RNAi
英文名稱： FLT3 Pre-design Chimera RNAi
產品編號： H00002322-R04
產品價格： 0
產品產地： 臺灣
品牌商標： Abnova
更新時間： null
使用范圍： null
亞諾法生技股份有限公司（Abnova)
- 聯系人 :
- 地址 : 臺灣臺北市內湖區洲子街 108 號 9 樓
- 郵編 : 11493
- 所在區域 : 臺灣
- 電話 : +886-920**1152 點擊查看
- 傳真 : 點擊查看
- 郵箱 : sales@abnova.com.tw
- Specification
- Product Description:
- Homo sapiens fms-related tyrosine kinase 3 (FLT3), mRNA.
- Reactivity:
- Human
- Storage Instruction:
- Store at -20°C, do not exceed 4 - 5 freeze-thaw cycles to ensure product integrity.
- Supplied Product:
- DEPC water
- Target Refseq:
- NM_004119
- Target Region:
- Coding sequence
- Note:
- Position of the Chimera RNAi.
-
- Publication Reference
- 1.
- dsCheck: highly sensitive off-target search software for double-stranded RNA-mediated RNA interference.
Naito Y, Yamada T, Matsumiya T, Ui-Tei K, Saigo K, Morishita S.Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W589-91.
- 2.
- Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect.
Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K.Nucleic Acids Res. 2008 Apr;36(7):2136-51. Epub 2008 Feb 11.
- 3.
- Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.
Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K.Nucleic Acids Res. 2004 Feb 9;32(3):936-48. Print 2004.
- 4.
- siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.
Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K.Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W124-9.
- Application Image
- RNAi Knockdown
- Entrez GeneID:
- 2322
- Gene Name:
- FLT3
- Gene Alias:
- CD135,FLK2,STK1
- Gene Description:
- fms-related tyrosine kinase 3
- Gene Ontology:
- Hyperlink
- Gene Summary:
- This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq
- Other Designations:
- CD135 antigen,FL cytokine receptor,FLT3 receptor tyrosine kinase,OTTHUMP00000042340,fetal liver kinase 2,growth factor receptor tyrosine kinase type III,stem cell tyrosine kinase 1,tyrosine-protein kinase receptor FLT3
- Related Disease
- Acute Disease
- Cardiovascular Diseases
- Cell Transformation, Neoplastic
- Chromosome Aberrations
- Diabetes Mellitus, Type 2
- Disease Progression
- Down Syndrome
- Edema
- Fractures, Spontaneous
- Genetic Predisposition to Disease
- Leukemia
- Leukemia, B-Cell, Acute
- Leukemia, chronic myeloid
- Leukemia, Lymphocytic, Acute, L1
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic